If I can remember that multifaceted question, first of all, the regulation changes in June of last year do not affect us, really--not at all. It was an interesting thing, and there were pros and cons expressed by the industry and the stakeholders and so on.
With regard to the question about the R and D, the reason they're not investing more in Canada is very complex, and we don't have the answer for it. It may be the subject of some inquiry by an organization other than ours. We have no regulatory power with regard to research and development. We simply report, and we're reporting basically what the pharmaceutical industry tells us.
Finally, regarding the generics, when we started reporting on generics, we were surprised to see that Canada is actually higher than, let's say, the United States. So the prices of generic pharmaceuticals in Canada are quite a bit higher than those in the United States. With regard to patented medicine, as you've heard, we are below the international median, so we're doing well on patented medicines. On generics, however, we're not doing so well. When you dig down into the subject, you'll realize that in Canada there's very little competition in the generic pharmaceutical industry. Basically, 90% of sales are by two manufacturers, and I believe one of those does actually quite a bit more than the other, so there's no competition.